Case Report: Response to ivosidenib in patients with cholangiocarcinoma: a clinical perspective with illustrative cases
-
By
-
Yannick Buccella
-
June 2, 2026
-
Objective:
To illustrate the clinical use and efficacy of ivosidenib in patients with cholangiocarcinoma (CCA) through case studies.
Key Findings:
- Ivosidenib can lead to durable responses and improved survival in CCA patients with IDH1 mutations.
- Tumor shrinkage with ivosidenib is infrequent, as seen in only 2% of patients in the ClarIDHy study.
- Older patients may face additional risks, such as malignant hypercalcemia, when treated with ivosidenib.
Interpretation:
The case studies illustrate the benefits and challenges of using ivosidenib in real-world settings for CCA patients with IDH1 mutations.
Limitations:
- The findings are based on a limited number of case studies presented and may not be generalizable to all CCA patients.
- The risk of hypercalcemia in older patients requires careful monitoring.
Conclusion:
